Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma

OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration

Saved in:
Bibliographic Details
Main Authors: Rocha,Talita Maira Bueno da Silveira da, Costa,Fortier Sergio, Pinto,Maeva Seo Gomes, Silva,Igor Campos da, Paes,Roberto Pinto, Chiattone,Carlos Sergio
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842013000400256
record_format ojs
spelling oai:scielo:S1516-848420130004002562013-10-10Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphomaRocha,Talita Maira Bueno da Silveira daCosta,Fortier SergioPinto,Maeva Seo GomesSilva,Igor Campos daPaes,Roberto PintoChiattone,Carlos Sergio Lymphoma, large B-cell, diffuse Central nervous system neoplasms/secondary Doxorubicin/administration & dosage Drug administration schedule Antineoplastic Agents/therapeutic use Multivariate analysis Risk factors OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.35 n.4 20132013-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256en10.5581/1516-8484.20130094
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Rocha,Talita Maira Bueno da Silveira da
Costa,Fortier Sergio
Pinto,Maeva Seo Gomes
Silva,Igor Campos da
Paes,Roberto Pinto
Chiattone,Carlos Sergio
spellingShingle Rocha,Talita Maira Bueno da Silveira da
Costa,Fortier Sergio
Pinto,Maeva Seo Gomes
Silva,Igor Campos da
Paes,Roberto Pinto
Chiattone,Carlos Sergio
Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
author_facet Rocha,Talita Maira Bueno da Silveira da
Costa,Fortier Sergio
Pinto,Maeva Seo Gomes
Silva,Igor Campos da
Paes,Roberto Pinto
Chiattone,Carlos Sergio
author_sort Rocha,Talita Maira Bueno da Silveira da
title Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
title_short Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
title_full Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
title_fullStr Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
title_full_unstemmed Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
title_sort secondary infiltration of the central nervous system in patients with diffuse large b-cell lymphoma
description OBJECTIVE: To investigate the incidence and risk factors of infiltration of the central nervous system after the initial treatment of diffuse large B-cell lymphoma in patients treated at Santa Casa de Misericórdia de São Paulo. METHODS: A total of 133 patients treated for diffuse large B-cell lymphoma from January 2001 to April 2008 were retrospectively analyzed in respect to the incidence and risk factors of secondary central nervous system involvement of lymphoma. Intrathecal prophylaxis was not a standard procedure for patients considered to be at risk. This analysis includes patients whether they received rituximab as first-line treatment or not. RESULTS: Nine of 133 (6.7%) patients developed central nervous system disease after a mean observation time of 29 months. The median time to relapse or progression was 7.9 months after diagnosis and all but one patient died despite the treatment administered. Twenty-six (19.5%) patients of this cohort received rituximab as first-line treatment and nine (7.1%) received intrathecal chemoprophylaxis. Of the nine patients that relapsed, seven (77.7%) had parenchymal central nervous system involvement; seven (77.7%) had stage III or IV disease; one (11.1%) had bone marrow involvement; two (22.2%) had received intrathecal chemoprophylaxis; and 3 (33.3%) had taken rituximab. In a multivariate analysis, the risk factors for this infiltration were being male, previous use of intrathecal chemotherapy and patients that were refractory to initial treatment. CONCLUSION: Central nervous system infiltration in this cohort is similar to that of previous reports in the literature. As this was a small cohort with a rare event, only three risk factors were important for this infiltration
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000400256
work_keys_str_mv AT rochatalitamairabuenodasilveirada secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
AT costafortiersergio secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
AT pintomaevaseogomes secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
AT silvaigorcamposda secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
AT paesrobertopinto secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
AT chiattonecarlossergio secondaryinfiltrationofthecentralnervoussysteminpatientswithdiffuselargebcelllymphoma
_version_ 1756423566739374080